Literature DB >> 8399806

Spontaneous hypertensive reactions with monoamine oxidase inhibitors.

M R Lavin1, A Mendelowitz, M H Kronig.   

Abstract

Despite long-standing concerns over hypertensive reactions, monoamine oxidase inhibitors (MAOIs) have grown in popularity and are now used in a variety of psychiatric disorders. The risk of hypertensive episodes is less than 1%. This is most likely the result of careful dietary instructions and prudent prescribing of concomitant medications. The possibility exists of spontaneous or unprovoked hypertensive crises in patients receiving MAOIs. In this report, we review the literature on spontaneous hypertensive episodes and present a case report. There has been a total of 11 cases described in six separate reports. We discuss the possible mechanism, risk factors, treatment, and safety of rechallenging the patients with the MAOI. Further research is needed to clarify this reaction. For now, it remains a rare but worrisome phenomenon. It should stand as an additional source of concern for clinicians who are already well aware of the risk of hypertensive episodes in patients receiving MAOIs.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8399806     DOI: 10.1016/0006-3223(93)90384-p

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  10 in total

1.  The role of monoamine oxidase inhibitors in current psychiatric practice.

Authors:  Jess G Fiedorowicz; Karen L Swartz
Journal:  J Psychiatr Pract       Date:  2004-07       Impact factor: 1.325

2.  In Reply: Spontaneous MAOI hypertensive reaction, not likely armodafinil - tranylcypromine interaction.

Authors:  Connor J Kinslow; Eliza C Miller
Journal:  J Neurol Sci       Date:  2019-01-08       Impact factor: 3.181

3.  The trace amine theory of spontaneous hypertension as induced by classic monoamine oxidase inhibitors.

Authors:  Vincent Van den Eynde
Journal:  J Neural Transm (Vienna)       Date:  2021-08-09       Impact factor: 3.575

Review 4.  Efficacy and tolerability of pharmacotherapies for borderline personality disorder.

Authors:  Silvio Bellino; Erika Paradiso; Filippo Bogetto
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

Review 5.  A reassessment of the safety profile of monoamine oxidase inhibitors: elucidating tired old tyramine myths.

Authors:  Peter Kenneth Gillman
Journal:  J Neural Transm (Vienna)       Date:  2018-09-25       Impact factor: 3.575

Review 6.  Comparative tolerability profiles of the newer versus older antidepressants.

Authors:  M V Rudorfer; H K Manji; W Z Potter
Journal:  Drug Saf       Date:  1994-01       Impact factor: 5.606

7.  Monoamine Oxidase Inhibitors (MAOIs) in Psychiatric Practice: How to Use them Safely and Effectively.

Authors:  Samuel R Chamberlain; David S Baldwin
Journal:  CNS Drugs       Date:  2021-07-09       Impact factor: 5.749

8.  Cardiologic side effects of psychotropic drugs.

Authors:  Giuseppe Marano; Gianandrea Traversi; Enrico Romagnoli; Valeria Catalano; Marzia Lotrionte; Antonio Abbate; Giuseppe Biondi-Zoccai; Marianna Mazza
Journal:  J Geriatr Cardiol       Date:  2011-12       Impact factor: 3.327

Review 9.  Cardiovascular considerations in antidepressant therapy: an evidence-based review.

Authors:  Habibeh Yekehtaz; Mehdi Farokhnia; Shahin Akhondzadeh
Journal:  J Tehran Heart Cent       Date:  2013-10-28

10.  Nanoformulation improves antitumor efficacy of MAOI immune checkpoint blockade therapy without causing aggression-related side effects.

Authors:  James Brown; Zhe Li; Xi Wang; Yu Jeong Kim; Yu-Chen Wang; Yanning Zuo; Weizhe Hong; Pin Wang; Bo Li; Lili Yang
Journal:  Front Pharmacol       Date:  2022-09-01       Impact factor: 5.988

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.